Pharvaris (NASDAQ:PHVS - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 189,848 shares were traded during trading, an increase of 157% from the previous session's volume of 73,937 shares.The stock last traded at $16.43 and had previously closed at $16.72.
Analyst Upgrades and Downgrades
PHVS has been the subject of a number of research analyst reports. Wedbush reiterated an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday. Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th.
Get Our Latest Research Report on Pharvaris
Pharvaris Stock Up 4.5%
The stock has a fifty day moving average of $15.52 and a two-hundred day moving average of $17.10. The stock has a market cap of $877.43 million, a price-to-earnings ratio of -5.99 and a beta of -2.86.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). Equities research analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharvaris
Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in Pharvaris during the fourth quarter worth $64,000. KLP Kapitalforvaltning AS bought a new stake in Pharvaris during the fourth quarter valued at $111,000. Point72 Asset Management L.P. acquired a new stake in shares of Pharvaris during the fourth quarter worth $152,000. Finally, Legal & General Group Plc lifted its position in shares of Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
